drugset
drugset / Trial / NCT05132738

Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy

NCT05132738 ↗

Unknown 20 enrolled RenJi Hospital
NaSingle-groupOpen-labelTreatment

Summary

To explore the efficacy and safety of preoperative treatment of potentially resectable locally advanced or recurrent metastatic gastrointestinal stromal tumor (GIST) after failure of treatment.

Timeline

Start
2021-08-01
Primary completion
2023-11-30
Completion
2023-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ripretinib Small molecule 150 mg Oral

Indications

gastrointestinal stromal tumor